BAYER PRODUCT JOURNEYS
kerendia
Nubeqa
elizanetant
Get in touch
asundexiun
BAYER PATIENT JOURNEYS
Data Generation & Observational Studies (DGOS) Vision and Mission
What is there to know?
Using the sections below, navigate across our latest product journeys, developments, and key milestones. Explore our goals and forward-thinking behind each product journey:
Vision: Leverage Innovatie research and real-world data to improvde patient care.
Development and deployment of strategy in field facing resources, Value Propositions for the entire Bayer portfolio, Burden of Illness, BIM, CEA, Pipeline presentation, Ad-hoc analysis of BI data to support formulary position, Facilitate payer and health system research, Obtain Payer/PBM insights on formulary position, rationale and evidence requirements, Provide Value and Economic presentations to Advocacy and Public Policy decision makers, Develop interactive models using AI/ML to identify and characterize patient populations, Review and discussion of guidelines, pathways and impact on patient outcomes and total cost burden.
Mission: Serve as the center of excellence for data generation, data interpretation, and data communication to demonstrate the value of Bayer products and to improve the quality of healthcare in the United States.
Asundexiun
Elizanetant
Kerendia
Coming soon
Bayer Product Journeys
Click here to view Bayer Product Journeys
To view more information click here
For additional product information, please visit our US Medical Affairs site https://medicalaffairs.bayer.com/ Or scan the QR code below:
Product Information
Below explore the dates of resources from Pre-Approval, Product Launch (07/2021) to Post-Approval, OPDP (FDA - office of Prescription Drug Promotion) October 2023.
Kerendia Timeline
Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D)
Prevalence of CKD and ESKD within the T2D population in the United States.
The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease.
Fidelio - DKD Clinical Trial
The Healthcare Effectiveness Data and Information Set (HEDIS®) quality measure, Kidney Health Evaluation for Patients with Diabetes, underscores the importance of appropriate kidney health evaluation, defined as both UACR and eGFR assessments within a 12-month measurement period.
HEDIS Kidney Health Measure
Kerendia (finerenone) Prescribing Information.
PI
Important Information for Formulary and Population Health Decision Makers.
Value Proposition
Figaro-DKD Phase III Clinical trial and Fidelity Prespecified meta-analysis.
Label Update (Figaro-DKD & Fidelity Clinical Trials)
ADA – American Diabetes Association AACE – American Association of Clinical Endocrinology KDIGO/ADA Consensus Report KDIGO – Kidney Disease: Improving Global Outcomes
Guidelines Updates in Clinical Practice Recommendations
A Microsoft Excel®-based economic model was developed to evaluate the budget impact of finerenone in adult patients with CKD associated with T2D being treated with standard of care.
BIM & Plan Liability Model Budget Impact Model (BIM)
The model provides 5-year estimates of the incidence and costs associated with disease progression in patients with chronic kidney disease associated with type 2 diabetes.
SIM CKD Model
SGLT2i & Finerenone Safety Profiles. Real-world Data on SGLT2i Discontinuation Rates in Patients With T2D.
Open Access Step Therapy vs Open Access Therapy
The underdiagnosis of Chronic Kidney Disease (CKD) in patients with Type 2 Diabetes (T2D) may contribute to the low real-world utilization of guideline-directed medical therapy, leading to unchecked CKD progression and cardiovascular risks.
Unmet Clinical Needs
Urinary albumin-to-creatinine ratio (UACR) testing in patients with CKD associated with T2D.
Total Cost Of Care: Addressing the Total Cost of Care With KERENDIA® (finerenone)
KERENDIA is a nonsteroidal mineralocorticoid receptor antagonists (MRA) indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Click here to view product timeline journey
CKD in T2D
Click here for package insert
HEDIS – Kidney Health Measure
Label Update
BIM & Plan Liability Model
Guidelines
Open Access
Total Cost of Care
PRE APPROVAL
07/2021 PRODUCT LAUNCH
POST APPROVAL
BACK TO TOP
A Microsoft Excel®-based economic model was developed to evaluate the net plan liability impact of adding finerenone for adult patients with CKD associated with T2D being treated with standard of care.
Plan Liability Model
CKD in 2TD
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa ta lopot.
Click here to download
Figaro-DKD & Fidelity Clinical Trials
Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
Increasing costs associated with CKD progression for both commercial and Medicare patient.
Current gaps in care faced by patients with kidney disease.
How improvements in screening may impact the patient journey.
CKD associated with T2D – Landscape overview.
Kerendia Product Profile.
Kerendia distribution and patient support.
The net plan liability model reflects the perspective of a US third-party payer over a 3-year time horizon.
PATH study.
Opportunities to improve Guideline-Based Prescribing for KERENDIA® (finerenone)
Access restrictions for Kerendia
Click here to view and download KERENDIA® (finerenone) Plan Liability Model
Click here to view and download MA-FINE-US-0131-1_KERENDIA BIM
Coming soon.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna.Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus.Pellentesque habitant morbi tristique senectus et netus et malesuada fames.
BACK
Below eplore the dates of resources from pre-approval, July 9th, 2021 to post-approval, OPDP (FDA - office of Prescription Drug Promotion) October 2023.
Use the timeline below to follow our product timeline journey
Nubeqa Timeline
For any additional information or support, please don’t hesitate to get in contact with us! Together we can make a difference. Science for a better life.
Name: Lorem Ipsum Phone: 123456789 Email: Lorem@gmail.com
CDK in T2D Disease state education
Defining the Opportunity to assess outcomes for patients with CKD & T2D
Identifying Patients At Risk For Chronic Kidney Disease Associated With Type 2 Diabetes
CKD Associated with 2TD Diease state education brochure for payers
Finerenone Discussion For Formulary Decision Makers, CKD in T2D is a population health issue, Clinical and economic burden, Mechanism of disease and CKD progression, Clinical Overview & Finerenone P3 clinical program
Pre-approval information exchange (PIE) Deck, V2
Important Information for Formulary Decision Makers & CKD Associated with T2D
Value proposition slides
CKD Associated with T2D , Kerendia product profile & Important Safety Information for Kerendia
Value Proposition-abridged version
Prescribing Information
Package insert deck Obselete upon OPDP approval
Disease Progression and Associated Costs in Patients with CKD associated with T2D Treated with Kerendia, and to also simulate the incidence of ESRD & CV outcomes and its' associated costs using inputs based on the Fidelio DKD patient population
SIM CDK
BIM - estimate the cumulative incidence of ESRD and CV-events (HHF, MI, Stroke) and costs associated with CKD progression in patients with CKD associated with T2D over a 5-yr time horizon. Plan Liability Model - evaluate the budget impact of Kerendia in adult patients with CKD associated with T2D being treated with SOC, SOC as patient swer treated in the Fidelio clinincal trial, ACE/ARB, glucose lowering thepies/insulin/metformin/GLP-1/sGLT2i, statins
BIM - Excel and Plan Liability Model
Defining the opportunity to assess outcomes for Patients with CKD & T2D
Unmet needs deck CDK in T2D & Disease state V2
Updated VP with Figaro & Fidelity data, Overview of gaps in care in CKD associated with T2D, Kerendia proposed MOA, Summary of recommendation on the use of Kerendia from updated clinical practice guidelines, Key safety and efficacy data & Health Economic models reviewing the impact of Kerendia on health plan expenditures
Payer Value Prop V2.0
BIM - estimate the cumulative incidence of ESRD and CV-events (HHF, MI, Stroke) and costs associated with CKD progression in patients with CKD associated with T2D over a 5-yr time horizon
BIM updated with Figaro data
SIM CKD updated with Figaro data
Ensuring Appropriate Access to Finerenone for your Members with CKD Associated with T2D
Ensuring appropriate kidney health testing, diagnosis, and treatment can help reduce the total cost of care
Addressing the total cost of care
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum in rhoncus turpis
Unmet needs, not approved, target approval October 2023
05/13
Pre Approval
07/12
Launch Approval
01/22
Post Approval
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna. Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero. sed pulvinar ultricies, purus lectus malesuada libero, sit amet commodo magna eros quis urna. Nunc viverra imperdiet enim. Fusce est. Vivamus a tellus. Maecenas porttitor congue massa. Fusce posuere, magna sed pulvinar ultricies, purus lectus malesuada libero
Elizanetant Timeline
Asundexiun Timeline
Asundexiun:
